** Jyske Bank keeps "buy" rating for Genmab GMAB.CO, even though it notes uncertainty over Danish drug maker's partnership with Johnson & Johnson JNJ.N has weighed on its shares
** The clarification of the partnership, which concerns the Hexabody-CD38 cancer drug, could come as soon as this week, the broker says
** "Our feeling is that the market is predominantly leaning towards the deal not going through," says Jyske Bank, adding it bases this on the price movement over the past year
** Jyske Bank notes that the outcome of the decision is "very difficult to call," but assesses the market has partially priced in the negative outcome
** The broker also notes that at the current share price level new investors will get the entire pipeline for free
** But Jyske Bank says Genmab can put the uncertainty behind after the announcement and focus on overcoming the Darzalex patent expiration in 2030, when other products will become important
** Jyske Bank therefore sees less downside risk than upside potential
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.